Results 41 to 50 of about 23,087 (229)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis

, 2017
Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It leads to an increased risk of bone fractures – one of the major causes of disability in modern societies.
Ewa Milewska, Piotr Rynio, Elżbieta Kubala, Blazej Meczekalski, Radosław Słopień   +4 more
core   +1 more source

Therapeutic‐dose verapamil‐induced cardiogenic shock in an older patient: a case report

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background Calcium channel blocker (CCB) toxicity most commonly follows deliberate overdose. However, severe toxicity at therapeutic doses may occur in susceptible individuals. Severe CCB toxicity often presents with clinical features of bradycardia, hypotension, hyperglycaemia, and lactic acidosis.
Christopher Thuring, Maria Carey, Timothy Webber, Biswadev Mitra   +3 more
wiley   +1 more source

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study

, 2021
Objective:Denosumab is a humanized monoclonal antibody that targets the receptor activator of nuclear factor kappa-beta ligand. This study aimed to evaluate the effectiveness of denosumab, a new-generation drug, in treating postmenopausal osteoporosis ...
Nihal Tezel, Öznur Ecerkale, Damla Cankurtaran, Ece Ünlü Akyüz   +3 more
core   +1 more source

Factors Contributing to Improved Bone Mineral Density in Patients With Transfusion‐Dependent Thalassemia

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Advances in therapy have extended the life expectancy of patients with thalassemia to near that of the general population; complications such as endocrine disorders and osteoporosis remain prevalent. This study aimed to identify endocrine complications, factors associated with endocrine complications, and changes in bone mineral density (BMD ...
Cheng‐Ying Hsu, Hui‐Pin Hsiao, Shyh‐Shin Chiou, Pei‐Chin Lin, Yu‐Mei Liao, Wan‐Yi Hsu, Teng‐Hao Wang, Shuo‐Yu Wang   +7 more
wiley   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Journal of Bone Oncology
Background: Bone metastasis is a significant concern in advanced solid tumors, contributing to diminished patient survival and quality of life due to skeletal-related events (SREs). Denosumab (DMAB), a monoclonal antibody targeting the receptor activator
E. Mabrut, S. Mainbourg, J. Peron, D. Maillet, S. Dalle, C. Fontaine Delaruelle, E. Grolleau, P. Clezardin, E. Bonnelye, C.B. Confavreux, E. Massy   +10 more
doaj   +1 more source

Polypharmacy among adolescents and adults with cerebral palsy in a clinical setting

PM&R, EarlyView.
Abstract Background Adolescents and adults with cerebral palsy often experience multimorbidity related to their condition, which primarily affects movement and posture but is also associated with pain, epilepsy, mood disorders, and other conditions. As such, these patients are often prescribed a range of medications to manage symptoms, thereby putting ...
Caitlin Cassidy, Joshua C. Wiener, Karen Pratt, Laura Brunton   +3 more
wiley   +1 more source

The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study

Scientific Reports
The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98
Jun-Ki Moon, Jinyong Park, Yisack Yoo, Jae Youn Yoon, Sunhyung Lee, Pil Whan Yoon   +5 more
doaj   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source